Hyper-IgD syndrome or mevalonate kinase deficiency

Current Opinion in Rheumatology

Volumn 23, Issue 5, 2011, Pages 419-423

  Stoffels, Monique ^a   Simon, Anna ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

hyper IgD syndrome; interleukin 1; isoprenoid metabolism; mevalonate kinase deficiency

Indexed keywords

ALENDRONIC ACID; APRIL PROTEIN; B CELL ACTIVATING FACTOR; BETA DEFENSIN 3; C REACTIVE PROTEIN; CHOLESTEROL; FARNESOL; GERANIOL; GERANYLGERANIOL; GUANOSINE TRIPHOSPHATASE; HISTONE DEACETYLASE INHIBITOR; HLA DR ANTIGEN; IMMUNOGLOBULIN D; INFLIXIMAB; INTERLEUKIN 13; INTERLEUKIN 1BETA; INTERLEUKIN 4; LONAFARNIB; MANUMYCIN; MANUMYCIN A; MEVALONATE KINASE; MEVINOLIN; PAMIDRONIC ACID; PENTRAXIN 3; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SERUM AMYLOID A; SIMVASTATIN; TIPIFARNIB; UNCLASSIFIED DRUG; UNINDEXED DRUG;

BASOPHIL; CELL INFILTRATION; CHEMICAL REACTION KINETICS; CHOLESTEROL BLOOD LEVEL; CHRONIC HEPATITIS; CONGENITAL DYSERYTHROPOIETIC ANEMIA; CONJUNCTIVITIS; CYTOKINE RELEASE; DISEASE ACTIVITY; GENE INDUCTION; GENOTYPE PHENOTYPE CORRELATION; GERANYLGERANYLATION; HUMAN; HYPERIMMUNOGLOBULINEMIA D AND PERIODIC FEVER SYNDROME; IMMUNOGLOBULIN A NEPHROPATHY; INFLAMMATION; INNATE IMMUNITY; ISOPRENYLATION; KERATITIS; KERATOPATHY; LEUKOCYTE; MEDIATOR RELEASE; MEVALONATE KINASE DEFICIENCY; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PROTEIN INTERACTION; REVIEW;

ANIMALS; HUMANS; IMMUNOGLOBULIN D; INTERLEUKIN-1; MEVALONATE KINASE DEFICIENCY; MEVALONIC ACID; MICE; MONOMERIC GTP-BINDING PROTEINS; PHENOTYPE; SIGNAL TRANSDUCTION; TERPENES;

EID: 80052023093     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0b013e328349c3b1     Document Type: Review

References (22)

1. van der Hilst JC, Bodar EJ, Barron KS, et al. Long-term follow-up, clinical features, and quality of life in a series of 103 patients with hyperimmunoglobulinemia D syndrome. Medicine 2008; 87:301-310.
2. Pontillo A, Paoluzzi E, Crovella S. The inhibition of mevalonate pathway induces upregulation of NALP3 expression: new insight in the pathogenesis of mevalonate kinase deficiency. Eur J Hum Genet 2010; 18:844-847.
3. De Leo L, Marcuzzi A, Decorti G, et al. Targeting farnesyl-transferase as a novel therapeutic strategy for mevalonate kinase deficiency: in vitro and in vivo approaches. Pharmacol Res 2010; 61:506-510.
4. Marcuzzi A, Decorti G, Pontillo A, et al. Decreased cholesterol levels reflect a consumption of anti-inflammatory isoprenoids associated with an impaired control of inflammation in a mouse model of mevalonate kinase deficiency. Inflamm Res 2010; 59:335-338.
5. Marcuzzi A, Tommasini A, Crovella S, Pontillo A. Natural isoprenoids inhibit LPS-induced-production of cytokines and nitric oxide in aminobisphosphonate-treated monocytes. Int Immunopharmacol 2010; 10:639-642.
6. Marcuzzi A, Crovella S, Pontillo A. Geraniol rescues inflammation in cellular and animal models of mevalonate kinase deficiency. In Vivo 2011; 25:87-92.
7. Marcuzzi A, De Leo L, Decorti G et al. The farnesyl transferase inhibitors Tipifarnib and Lonafarnib inhibit cytokines secretion in a cellular model of mevalonate kinase deficiency. Pediatr Res 2011; 70:78-82.
8. Marcuzzi A, Pontillo A, De Leo L, et al. Natural isoprenoids are able to reduce inflammation in a mouse model of mevalonate kinase deficiency. Pediatr Res 2008; 64:177-182.
9. Mandey SH, Schneiders MS, Koster J, Waterham HR. Mutational spectrum and genotype-phenotype correlations in mevalonate kinase deficiency. Hum Mutat 2006; 27:796-802. (Pubitemid 44205073)
10. Kuijk LM, Beekman JM, Koster J, et al. HMG-CoA reductase inhibition induces IL-1beta release through Rac1/PI3K/PKB-dependent caspase-1 activation. Blood 2008; 112:3563-3573.
11. Hager EJ, Tse HM, Piganelli JD, et al. Deletion of a single mevalonate kinase (Mvk) allele yields a murine model of hyper-IgD syndrome. J Inherit Metab Dis 2007; 30:888-895. (Pubitemid 50003585)
12. Henneman L, Schneiders MS, Turkenburg M, Waterham HR. Compromized geranylgeranylation of RhoA and Rac1 in mevalonate kinase deficiency. J Inherit Metab Dis 2010; 33:625-632.
13. Simon A, Drewe E, van der Meer JW, et al. Simvastatin treatment for inflammatory attacks of the hyperimmunoglobulinemia D and periodic fever syndrome. Clin Pharmacol Ther 2004; 75:476-483. (Pubitemid 38534568)
14. Chen K, Xu W, Wilson M, et al. Immunoglobulin D enhances immune surveillance by activating antimicrobial, proinflammatory and B cell-stimulating programs in basophils. Nat Immunol 2009; 10:889-898.
15. de Wolff JF, Dickinson SJ, Smith AC, et al. Abnormal IgD and IgA1 O-glycosylation in hyperimmunoglobulinaemia D and periodic fever syndrome. Clin Exp Med 2009; 9:291-296.
16. Tahara M, Sakai H, Nishikomori R et al. Patient with neonatal-onset chronic hepatitis presenting with mevalonate kinase deficiency with a novel MVK gene mutation. Mod Rheumatol 2011 [Epub ahead of print].
17. Samkari A, Borzutzky A, Fermo E, et al. A novel missense mutation in MVK associated with MK deficiency and dyserythropoietic anemia. Pediatrics 2010; 125:e964-e968.
18. Kraus CL, Culican SM. Nummular keratopathy in a patient with hyper-IgD syndrome. Pediatr Rheumatol Online J 2009; 7:14.
19. Korppi M, Van Gijn ME, Antila K. Hyperimmunoglobulinemia D and periodic fever syndrome in children. Review on therapy with biological drugs and case report. Acta Paediatr 2011; 100:21-25.
20. Shendi HM, Walsh D, Edgar JD. Etanercept and anakinra can prolong febrile episodes in patients with hyperimmunoglobulin D and periodic fever syndrome. Rheumatol Int 2009. DOI: 10.1007/s00296-009-1322-8.
21. Bodar EJ, Simon A, Van Der Meer JW. Effects of the histone deacetylase inhibitor ITF2357 in autoinflammatory syndromes. Mol Med 2011; 17:363-368.
22. Steichen O, van der Hilst J, Simon A, et al. A clinical criterion to exclude the hyperimmunoglobulin D syndrome (mild mevalonate kinase deficiency) in patients with recurrent fever. J Rheumatol 2009; 36:1677-1681.